Full Press Release Details
MARLBOROUGH, Mass. , Sept. 17, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced key data that will be presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Diego , on September 21 - September 25 .
Data from the head-to-head IMPERIAL trial evaluating the ELUVIA™ Drug-Eluting Vascular Stent System and the Zilver® PTX® Stent for treatment of superficial femoral or proximal popliteal lesions will be featured during a late-breaking clinical trial session on Saturday, September 22 . Two-year outcomes data from the REPRISE III study, a head-to-head comparison of the LOTUS™ Aortic Valve System to the CoreValve™ Evolut™ R in high-risk patients with severe aortic stenosis, will also be highlighted at the meeting.
All presentations are listed in Pacific Time and will take place at the San Diego Convention Center.
PRESENTATIONS OF INTEREST (listed chronologically)
Friday, September 21
Saturday, September 22
Sunday, September 23
Monday, September 24
For more information, visit http://www.bostonscientific.com/en-US/medical-specialties/interventional-cardiology/conferences-and-events/tct.html or during TCT visit the Boston Scientific booth #507.
The company will also host an investor event and webcast on Monday, September 24 from 9:00 – 10:00 a.m. PT to provide a business update and answer questions from investors about the Boston Scientific cardiovascular portfolio. The event will be accessible at www.bostonscientific.com/investors . A replay of the webcast will be accessible at www.bostonscientific.com/investors beginning approximately one hour following the completion of the event.
In the U.S., the ELUVIA Stent System is an investigational device and is not available for sale. The LOTUS Valve system is not available for use or sale.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the acquisition, the financial and business impact of the transaction, product launches and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACT: Timette Nevala Manager, Communications (763) 494-1284 (office) [email protected]
Susie Lisa , CFA Investor Relations Boston Scientific Corporation (508) 683-5565 (office) [email protected]
SOURCE Boston Scientific Corporation